Accessibility Menu
20/20 Biolabs logo

20/20 Biolabs(NASDAQ) AIDX

Market Cap$6.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-98%
5 YearN/A
1 YearN/A
1 Month+6%
$0.52
-6.51%
-0.04Today
20/20 Biolabs last closing stock price
MetricPriceDate
Last closeUSD 0.522026-08-24
20/20 Biolabs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.83%USD 0.552026-08-17
1 month+5.54%USD 0.492026-07-24
3 month-49.2%USD 1.022026-05-26
Since inception-97.83%USD 23.852026-02-19

20/20 Biolabs Financials at a Glance

Market Cap

$6.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.04M

Net Income (TTM)

-$5.81M

EPS (TTM)

-$0.72

P/E Ratio

-0.72

Dividend

$0.00

Beta (Volatility)

-0.34 (Low)

Price

$0.52

Volume

469

Open

$0.56

Previous Close

$0.52

Daily Range

$0.51 - $0.56

52-Week Range

$0.40 - $50.00

Estimated Earnings Date

Sep 2, 2026

AIDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 20/20 Biolabs

20/20 Biolabs helps people detect cancer early with simple blood tests. Its services also screen for chronic diseases and support other labs in launching new tests. Firefighters, veterans, and health clinics use these tools to catch health risks sooner.

Products and Services

  • OneTest for Cancer (88% of 2025 revenue): Multi-cancer blood test using artificial intelligence, aimed at early detection for adults and high-risk groups.
  • OneTest for Longevity: Blood test for chronic inflammation, launched in February 2026, marketed to employers and wellness programs.
  • BioCheck (8% of 2025 revenue): Field kit for detecting bioterror agents in suspicious powders, used by emergency responders.
  • CLIAx Shared Lab (4% of 2025 revenue): Laboratory space and support for diagnostic startups entering the U.S. market.
  • Cancer Screening SaaS: Software platform delivering cancer risk algorithms to healthcare providers.

Growth and Expansion

  • Launched OneTest for Longevity in February 2026, expanding into chronic disease screening.
  • Formed partnerships with Giant Food for retail and at-home test sales in 2025.
  • Secured exclusive U.S. rights for BioInfra’s cancer detection technology and Connecting Health Innovations’ dietary index in 2025.
  • Expanded plans for the CLIAx shared lab platform to support overseas diagnostics startups in 2025.
  • Completed direct listing on Nasdaq in February 2026 and raised $5 million in a concurrent private placement.

What Makes 20/20 Biolabs Stand Out

The company uses artificial intelligence to improve blood test accuracy and affordability. Its at-home and retail collection options make cancer screening more accessible. The shared lab model helps other diagnostics companies enter the U.S. market faster.

Five Things You Need to Know

  • 2025 revenue was $2.05 million, up 16.7% from 2024.
  • Gross margin improved to 29.6% in 2025, up from 20.6% in 2024.
  • Net loss narrowed to $3.74 million in 2025, from $5.55 million in 2024.
  • OneTest for Cancer accounted for 88% of 2025 revenue.
  • Cash and equivalents were $1.03 million at year-end 2025.

Bottom Line

20/20 Biolabs has shifted from legacy products to AI-driven cancer and wellness testing. The company continues to adapt through partnerships, new launches, and a focus on accessible diagnostics.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

14

CEO

Jonathan Cohen

Website

2020biolabs.com

Headquarters

Gaithersburg, MD 20877, US

AIDX Financials

Key Financial Metrics (TTM)

Gross Margin

31.52%

Operating Margin

-215.69%

Net Income Margin

-285.00%

Return on Equity

176.20%

Return on Capital

-0.26%

Return on Assets

-94.96%

Earnings Yield

-1.39%

Dividend Yield

0.00%

Payout Ratio

-2.09%

Stock Overview

Market Cap

$6.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.77M

Volume

469

Avg. Volume

664.02K

Financials (TTM)

Gross Profit

$643.09K

Operating Income

-$4.40M

EBITDA

-$4.34M

Operating Cash Flow

-$2.94M

Capital Expenditure

$5.35K

Free Cash Flow

-$2.94M

Cash & ST Invst.

$4.55M

Total Debt

$572.45K

20/20 Biolabs Performance Analysis

20/20 Biolabs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,059,14514.9%
20232023-12-31USD 1,424,304-87.1%
20242024-12-31USD 1,752,34323.0%
20252025-12-31USD 2,045,13316.7%
20/20 Biolabs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-3128.8%
Q12026-03-31-34.4%
Q22026-06-30106.7%
20/20 Biolabs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.234.5%
20232023-12-31USD -1.34N/A
20242024-12-31USD -1.16-13.4%
20252025-12-31USD -0.36-69.1%
20/20 Biolabs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-3123.5%
Q12026-03-31-115.4%
Q22026-06-307.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$730.57K

+36.3%

Gross Profit

$304.73K

+86.9%

Gross Margin

41.71%

N/A

Market Cap

$6.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$472.69K

N/A

Employees

14

N/A

Net Income

-$1.51M

-20.6%

EBITDA

-$1.23M

-0.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.55M

+154.8%

Total Debt

$572.45K

-62.2%

Accounts Receivable

$291.49K

+115.5%

Inventory

$111.04K

+135.4%

Long Term Debt

$379.72K

-71.8%

Short Term Debt

$192.73K

+16.3%

Return on Assets

-94.96%

N/A

Return on Invested Capital

-1.23%

N/A

Free Cash Flow

-$600.11K

+57.5%

Operating Cash Flow

-$605.46K

+57.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,665.09-0.00%
^DJIDJI
$53,425.01+0.00%
^IXICNASDAQ
$26,080.69-0.00%
BTCBitcoin
$79,035.00+0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.16-0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$50.75+0.08%
IBITiShares Bitcoin Trust
$44.64+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.19+0.03%

Questions About AIDX

What is the current price of 20/20 Biolabs?

20/20 Biolabs is trading at $0.52 per share.

What is the 52-week range for 20/20 Biolabs?

Over the past 52 weeks, 20/20 Biolabs has traded between $0.40 and $50.00.

How much debt does 20/20 Biolabs have?

As of the most recent reporting period, 20/20 Biolabs reported total debt of $572.45K.

How much cash does 20/20 Biolabs have on hand?

20/20 Biolabs reported $4.55M in cash and cash equivalents in its most recent financial results.

What is 20/20 Biolabs’s dividend yield?

20/20 Biolabs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services